# Trial Comparing Cetuximab With Pemetrexed/Cetuximab Therapy for Non-Small Cell Lung Cancer

> **NCT00203931** · PHASE2 · TERMINATED · sponsor: **University of Chicago** · enrollment: 55 (actual)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Cetuximab
- **DRUG:** Pemetrexed

## Key facts

- **NCT ID:** NCT00203931
- **Lead sponsor:** University of Chicago
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-03
- **Primary completion:** 2008-11
- **Final completion:** 2009-11
- **Target enrollment:** 55 (ACTUAL)
- **Why stopped:** Slow accrual and evidence from other studies showing benefit of early initiation of pemetrexed after first-line therapy
- **Last updated:** 2014-03-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00203931

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00203931, "Trial Comparing Cetuximab With Pemetrexed/Cetuximab Therapy for Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00203931. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*